Albumin and Crystalloid Administration in Septic Shock

Septic Shock Clinical Trial

— ALCAMIST  

Official title:

Albumin and Crystalloid Administration in Septic Shock (ALCAMIST): Multi-center, Open Labelled Randomized Controlled Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05148286
• Other study ID #: ALCAMIST trial
• Status: Recruiting
• Phase: Phase 4
• Start date: January 17, 2022
• Est. completion date: December 31, 2024

Study information

• Verified date: June 2023
• Source: Asan Medical Center
• Contact: Sang-Min Kim, Dr.
• Phone: 82-10-3010-0730
• Email: swdarkhorse[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The current guideline emphasizes fluid resuscitation as the mainstay of initial management for septic shock. Albumin has the oncotic activity to maintain intravascular volumes with additional beneficial properties in sepsis. Prior studies showed that the replacement of albumin might have survival advantages in patients with septic shock. The investigators aim to assess whether the early administration of albumin with crystalloid as initial fluid resuscitation improves survival in patients with septic shock compared to resuscitation without albumin.

Description:

Sepsis is a leading cause of mortality worldwide, contributing to an estimated 11 million deaths in 2017-or 20% of all global deaths. Due to recent advances in the medical management and treatment of sepsis, the mortality of sepsis has been declined in these years, but still stayed at a high level. From 2004, the Surviving Sepsis Campaign (SSC) suggested a protocolized bundle therapy to facilitate implementation at the bedside with a defined target. Recent guideline states that this resuscitation bundle treatment should be initiated within 1 h of the emergency department (ED) triage time, named as 1-h bundle. Fluid resuscitation, which is the mainstay of treatment to restore a patient's tissue perfusion, is associated with outcome in emergency department patients. The current guideline recommends that crystalloid for initial fluid resuscitation in sepsis and albumin can be additionally administered when patients require substantial amounts of crystalloid. Besides its oncotic functions to provide adequate intravascular volume, albumin has several beneficial properties for sepsis patients, including binding and transport of various endogenous molecules, anti-inflammatory and anti-oxidative effects, and modulation of nitric oxide metabolism. In 2004, a large randomized, prospective, double-blind study was performed in 7000 critically ill patients (SAFE study) to evaluate the effect of volume replacement therapy with human albumin on the outcome compared to only crystalloid. Although the survival rates were similar between the groups, a post hoc analysis of 1218 patients with severe sepsis showed improved survival in the albumin group compared to crystalloid alone. Furthermore, the ALBumin Italian Outcome Sepsis (ALBIOS) study investigated the effect of albumin administration and maintenance of serum albumin concentrations to at least 30 g/l on outcome in patients with severe sepsis and septic shock. This study showed a similar result to SAFE study that no difference on the outcome between the groups. Nevertheless, in the 1121 patients with septic shock, 90-day mortality was lower in the albumin group (564 patients) than in the non-albumin group (43.6 vs. 49%, p = 0.03). Recently, a retrospective study which evaluated the effect of administration of albumin combined with crystalloids in septic patients showed improved survival in 28 days. Therefore, accumulating evidence suggests that early albumin administration may provide a survival benefit in patients with severe and advanced sepsis. However, no prospective, randomized trial has adequately studied this hypothesis in patients with septic shock. The aim of the ALCAMIST (ALbumin and Crystalloid AdMinistration In SepTic shock) study is to investigate the effect of albumin and crystalloid administration as an initial fluid choice in septic shock compared to crystalloid alone on patient survival.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 2426
• Est. completion date: December 31, 2024
• Est. primary completion date: September 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult patients (= 18 years) who visit an ED directly and are suspected of sepsis with shock
• Shock is defined as hypotension (mean arterial blood pressure (MAP) < 65 or systolic blood pressure < 80) and tissue hypoperfusion such as an initial serum lactate level = 4 mmol/dL.

Exclusion Criteria:

• patients who are transferred from another hospital after initial fluid administration
• patients who have set limitations on treatment (e.g. patients with a signed do-not-resuscitate order)
• patients with moribund conditions with life expectancy less than 28 days due to secondary diseases or advanced malignant disease and palliative situations with life expectancy less than 6 months
• patients who have been administered albumin before enrollment
• patients who have known hypersensitivity to albumin
• Clinical conditions, where albumin administration may be unfavorable (e.g. pulmonary edema, congestive heart failure, traumatic brain injury)
• lactation
• patients who do not voluntarily consent to participate in the trial.

Related Conditions & MeSH terms

• Septic Shock
• Shock
• Shock, Septic

Intervention

Drug:
• Treatment
For the treatment group, 200cc of 20% human albumin with 15 cc per kg of crystalloid will be administered over 1~2h for initial fluid resuscitation. The treating physicians can choose the type of fluid, such as balanced fluid or isotonic saline.
• Placebo
For the control group, 30 cc per kg of crystalloid will be administered according to the usual practice. The treating physicians can choose the type of fluid, such as balanced fluid or isotonic saline.

Locations

Country	Name	City	State
Korea, Republic of	Asan Medical Center	Seoul

Sponsors (9)

Lead Sponsor	Collaborator
Asan Medical Center	Chungnam National University Hospital, Gangnam Severance Hospital, Hanyang University, Korea University Ansan Hospital, Samsung Medical Center, Seoul National University Bundang Hospital, Seoul National University Hospital, SMG-SNU Boramae Medical Center

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	28-day all-cause mortality	The 28-day all-cause mortality in septic shock patient after admission will be evaluated	28-days
Secondary	90-day all-cause mortality	All-cause death within 90 days	90 days
Secondary	ICU mortality	All-cause death during ICU admission	28 days
Secondary	Hospital mortality	All-cause death during hospitalization	28 days
Secondary	The Sequential organ Failure Assessment (SOFA) score	The SOFA score will be recorded daily up to 28 days after randomization. Death within 72 hours will be counted as the maximum SOFA score.	28 days
Secondary	Intensive Care Unit (ICU) stay	The total length of ICU stay will be determined from the date of ICU admission until the patient is discharged from the ICU or the date of death from any cause, assessed up to 90 days after the first day of admission.	90 days
Secondary	7-day mortality	All-cause death within 7 days	7 days
Secondary	Ventilator free days	Days without ventilator within 28 days from admission	28 days
Secondary	Vasopressor free days	Days without vasopressor within 28 days from admission	28 days
Secondary	Total amount of fluid administration	Total amount of fluid administration during hospital admission	3 day, 7 day, 28 day
Secondary	Total fluid balance	Fluid balance will be recorded daily up to 28 days after randomization	28 days
Secondary	Maximum dose of vasopressor use	Maximum dose of vasopressor during hospital admission	28 days
Secondary	Renal replacement therapy	Whether renal replacement therapy was initiated during hospital admission after randomization.	28 days
Secondary	Safety-related parameters	Occurrence of adverse event, serious adverse event (e.g. anaphylactic shock, hypervolemia, pulmonary edema)	28 days